title: Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method.
abstract: Isavuconazole is a novel expanded-spectrum triazole, which has recently been approved by the FDA as an orphan drug to treat invasive aspergillosis and is currently being studied in phase III clinical trials for invasive candidiasis. The susceptibility of relatively few clinical isolates has been reported. In this study, the isavuconazole susceptibilities of 1,237 Aspergillus and 2,010 Candida geographically diverse clinical isolates were determined by EUCAST methodology at four European mycology laboratories, producing the largest multicenter data set thus far for this compound. In addition, a blinded collection of 30 cyp51A mutant Aspergillus fumigatus clinical isolates and 10 wild-type isolates was tested. From these two data sets, the following preliminary epidemiological cutoff (ECOFF) values were suggested: 2 mg/liter for Aspergillus fumigatus, Aspergillus terreus, and Aspergillus flavus; 4 mg/liter for Aspergillus niger; 0.25 mg/liter for Aspergillus nidulans; and 0.03 mg/liter for Candida albicans, Candida parapsilosis, and Candida tropicalis. Unfortunately, ECOFFs could not be determined for Candida glabrata or Candida krusei due to an unexplained interlaboratory MIC variation. For the blinded collection of A. fumigatus isolates, all MICs were ≤2 mg/liter for wild-type isolates. Differential isavuconazole MICs were observed for triazole-resistant A. fumigatus isolates with different cyp51A alterations: TR34/L98H mutants had elevated isavuconazole MICs, whereas isolates with G54 and M220 alterations had MICs in the wild-type range, suggesting that the efficacy of isavuconazole may not be affected by these alterations. This study will be an aid in interpreting isavuconazole MICs for clinical care and an important step in the future process of setting official clinical breakpoints.
authors: Department of Molecular and Clinical Pharmacology, Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
authors: Susan J
authors: SJ
authors: Howard
authors: Cornelia
authors: C
authors: Lass-Flörl
authors: Manuel
authors: M
authors: Cuenca-Estrella
authors: Alicia
authors: A
authors: Gomez-Lopez
authors: Maiken C
authors: MC
authors: Arendrup
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000382:microbiology; D001230:Aspergillus / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development / Q000302:isolation & purification; D002175:Candida / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development / Q000302:isolation & purification; D058365:Candidiasis, Invasive / Q000188:drug therapy / Q000382:microbiology; D054796:Drug Dosage Calculations; D025141:Drug Resistance, Fungal / Q000235:genetics; D005060:Europe; D006801:Humans; D008826:Microbial Sensitivity Tests; D009154:Mutation; D009570:Nitriles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D009570:Nitriles; D011725:Pyridines; D014230:Triazoles; C508735:isavuconazole
references: Clin Microbiol Infect. 2008 Oct;14(10):982-4
references: 18828858
references: Antimicrob Agents Chemother. 2012 Aug;56(8):4196-201
references: 22615291
references: J Antimicrob Chemother. 2006 Jan;57(1):135-8
references: 16284102
references: Antimicrob Agents Chemother. 2009 Mar;53(3):1185-93
references: 19104024
references: Clin Microbiol Infect. 2012 Jul;18(7):E246-7
references: 22563750
references: Antimicrob Agents Chemother. 2007 May;51(5):1818-21
references: 17307977
references: Antimicrob Agents Chemother. 2009 May;53(5):2223-4
references: 19258264
references: Antimicrob Agents Chemother. 2009 Apr;53(4):1645-7
references: 19164153
references: Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):759-65
references: 22530880
references: Antimicrob Agents Chemother. 2013 Aug;57(8):3823-8
references: 23716059
references: Mycoses. 2011 Sep;54(5):e583-9
references: 21518026
references: Antimicrob Agents Chemother. 2009 Mar;53(3):958-66
references: 19075045
references: J Clin Microbiol. 2013 Aug;51(8):2608-16
references: 23740727
references: Diagn Microbiol Infect Dis. 2011 Dec;71(4):370-7
references: 21937186
references: Med Mycol. 2011 Apr;49 Suppl 1:S90-5
references: 20795765
references: Antimicrob Agents Chemother. 2009 Jan;53(1):24-34
references: 18955533
references: Clin Infect Dis. 2010 Jan 1;50(1):27-36
references: 19951112
references: Clin Infect Dis. 2008 Jan 15;46(2):201-11
references: 18171251
references: Antimicrob Agents Chemother. 2008 Apr;52(4):1396-400
references: 18212101
references: Clin Microbiol Infect. 2013 Jun;19(6):E278-80
references: 23413937
references: Clin Microbiol Infect. 2012 Jul;18(7):E248-50
references: 22540149